| Cat. No. |
Product Name / Activity |
| 5807 |
M 084 hydrochloride |
| TRPC4/5 channel blocker; antidepressant and anxiolytic |
| 3629 |
M 1145 |
| Potent and selective GAL2 agonist |
| 4917 |
M 25 |
| Potent Smoothened (Smo) receptor antagonist |
| 6067 |
M 30 dihydrochloride |
| Potent and non-selective MAO inhibitor; also an iron chelator and antioxidant |
| 2771 |
M 344 |
| Histone deacetylase inhibitor |
| 1941 |
m-3M3FBS |
| Phospholipase C activator |
| 1942 |
o-3M3FBS |
| Inactive analog of m-3M3FBS (Cat. No. 1941) |
| 3425 |
M40 |
| Potent, non-selective galanin receptor antagonist |
| 2697 |
M617 |
| Selective GAL1 agonist |
| 5705 |
M62812 |
| TLR-4 inhibitor |
| 5324 |
M8 B hydrochloride |
| Potent and selective TRPM8 channel blocker |
| 2698 |
M871 |
| Selective GAL2 antagonist |
| 4934 |
MA 2029 |
| Potent and selective, competitive motilin receptor antagonist; orally active |
| 6382 |
MAIT 203 |
| APC-Asef (RhoGEF4) interaction inhibitor |
| 0711 |
MAP4 |
| Potent group II mGlu agonist; also group III mGlu antagonist |
| 1878 |
MAPK Cascade Inhibitor Tocriset™ |
| Selection of 5 MAPK cascade inhibitors (Cat. Nos. 1110, 1213, 1321, 1144 and 1202) |
| 2196 |
3-MATIDA |
| Potent and selective mGlu1 antagonist |
| 6799 |
MB 0223 |
| Dynamin-related GTPase DRP1 partial inhibitor |
| 6618 |
MB 05032 |
| Potent FBPase inhibitor; promotes HSC expansion |
| 1900 |
[Ala107]-MBP (104-118) |
| Protein kinase C inhibitor |
| 1901 |
[Ala113]-MBP (104-118) |
| Protein kinase C inhibitor |
| 4077 |
MC 1568 |
| Selective HDAC class IIa inhibitor |
| 5727 |
MC 1742 |
| Potent class I and IIb HDAC inhibitor |
| 3806 |
MCH (human, mouse, rat) |
| Potent endogenous MCH agonist |
| 3434 |
[Ala17]-MCH |
| Potent MCH receptor agonist |
| 3438 |
MCL 0020 |
| Selective MC4 receptor antagonist |
| 3763 |
MCOPPB trihydrochloride |
| Potent NOP receptor agonist |
| 0336 |
(RS)-MCPG |
| Non-selective mGlu antagonist |
| 3696 |
(RS)-MCPG disodium salt |
| Non-selective mGlu antagonist; disodium salt of (RS)-MCPG (Cat. No. 0336) |
| 0337 |
(S)-MCPG |
| Non-selective mGlu antagonist; active isomer of (RS)-MCPG (Cat. No. 0336) |
| 4205 |
MDA 19 |
| CB2 agonist |
| 4173 |
MDL 100907 |
| Potent and selective 5-HT2A antagonist |
| 0870 |
MDL 11,939 |
| 5-HT2A antagonist |
| 1436 |
MDL 12330A hydrochloride |
| Adenylyl cyclase inhibitor; also cyclic nucleotide PDE inhibitor |
| 1146 |
MDL 28170 |
| Potent, selective calpain and cathepsin B inhibitor |
| 1194 |
MDL 29,913 |
| Selective NK2 antagonist |
| 0640 |
MDL 72222 |
| 5-HT3 antagonist |
| 3709 |
MDL 72527 |
| Polyamine oxidase (PAO) inhibitor |
| 0412 |
MDL 72832 hydrochloride |
| Potent 5-HT1A ligand |
| 0411 |
MDL 73005EF hydrochloride |
| Potent and selective 5-HT1A partial agonist |
| 3027 |
(±)-MDMA hydrochloride |
| Inhibitor of 5-HT and dopamine uptake; hallucinogenic |
| 5785 |
MDNI-caged-L-glutamate |
| Stable photoreleaser of L-glutamate |
| 5054 |
ME 0328 |
| Selective PARP-3 inhibitor |
| 4615 |
MEDICA 16 |
| FFA1 (GPR40) agonist; also inhibits ATP citrate lyase |
| 1632 |
MEN 10376 |
| Potent, selective NK2 antagonist |
| 3978 |
MEN 11270 |
| Selective B2 antagonist; analog of HOE 140 (Cat. No. 3014) |
| 5875 |
MES sodium salt |
| Buffering agent |
| 5887 |
MES, free acid |
| Commonly used buffer |
| 4438 |
MFZ 10-7 |
| Negative allosteric modulator of mGlu5 receptors |
| 3358 |
MG 101 |
| Calpain inhibitor; activates p53-dependent apoptosis |
| 1748 |
MG 132 |
| Proteasome and calpain inhibitor. Inhibits NF-κB activation |
| 6033 |
(R)-MG 132 |
| Potent 20S proteasome inhibitor |
| 1356 |
MG 624 |
| α7 neuronal nAChR antagonist |
| 5604 |
MI 14 |
| Potent and selective PI 4-kinase IIIβ inhibitor |
| 5647 |
MI 192 |
| Potent and selective HDAC2/3 inhibitor |
| 4707 |
MI 2 dihydrochloride |
| Menin-MLL interaction inhibitor |
| 4848 |
MI 2 (MALT1 inhibitor) |
| MALT1 inhibitor |
| 4762 |
MIM1 |
| Mcl-1 inhibitor; proapoptotic |
| 3362 |
MIRA-1 |
| Restores mutant p53 activity; proapoptotic |
| 4063 |
MJ 15 |
| Potent and selective CB1 antagonist |
| 4415 |
MK 0343 |
| GABAA partial agonist; displays subtype selectivity |
| 5272 |
MK 0677 |
| High affinity ghrelin receptor agonist |
| 4622 |
MK 1903 |
| Potent and selective GPR109A (HCA2) agonist |
| 0941 |
MK 212 hydrochloride |
| 5-HT2C agonist |
| 4014 |
MK 217 |
| Inhibitor of farnesyl diphosphate synthase (FPPS) and osteoclast-mediated bone resorption |
| 5842 |
MK 386 |
| Potent, selective human type 1 5α-reductase inhibitor |
| 2338 |
MK 571 |
| Potent CysLT1 (LTD4) inverse agonist. Also MRP1 inhibitor |
| 0924 |
(+)-MK 801 maleate |
| Non-competitive NMDA antagonist; acts at ion channel site |
| 0955 |
(-)-MK 801 maleate |
| NMDA antagonist; less active enantiomer of (+)-MK 801 |
| 1311 |
MK 886 |
| Inhibitor of 5-lipoxygenase-activating protein (FLAP) |
| 5547 |
MK6-83 |
| TRPML channel activator |
| 4621 |
MKT 077 |
| Binds mot-2; selectively cytotoxic in cancer cells |
| 4854 |
ML 00253764 hydrochloride |
| Melanocortin MC4 receptor antagonist; brain penetrant |
| 3499 |
ML 10302 hydrochloride |
| Potent and selective 5-HT4 partial agonist |
| 4899 |
ML 120B dihydrochloride |
| Novel IKK2-selective inhibitor |
| 4354 |
ML 130 |
| Inhibits NOD1-induced NF-κB activation |
| 4549 |
ML 133 hydrochloride |
| Kir2 channel blocker |
| 4266 |
ML 141 |
| Selective Cdc42 Rho family inhibitor |
| 4172 |
ML 145 |
| GPR35 antagonist |
| 5161 |
ML 154 |
| Potent Neuropeptide S receptor antagonist |
| 4570 |
ML 161 |
| Inhibits PAR1-mediated platelet activation |
| 4653 |
ML 171 |
| Selective NADPH oxidase 1 (NOX1) inhibitor |
| 4957 |
ML 179 |
| Selective liver receptor homolog 1 (LRH1) inverse agonist |
| 5599 |
ML 18 |
| BRS-3 antagonist; also GRPR agonist |
| 6668 |
ML 184 |
| Selective GPR55 agonist; also promotes NSC proliferation and differentiation |
| 4866 |
ML 190 |
| Selective κ opioid receptor antagonist |
| 4860 |
ML 193 |
| Potent, selective GPR55 antagonist |
| 4732 |
ML 204 |
| Selective TRPC4 blocker |
| 5987 |
(±)-ML 209 |
| RORγt inverse agonist; suppresses Th17 cell differentiation |
| 6429 |
ML 210 |
| Selectively kills mutant HRAS-expressing cells; glutathione peroxidase inhibitor; induces ferroptosis |
| 4519 |
ML 213 |
| KV7.2 and KV7.4 channel opener |
| 4507 |
ML 218 hydrochloride |
| CaV3.x blocker |
| 4748 |
ML 221 |
| Apelin antagonist |
| 4565 |
ML 228 |
| HIF pathway activator |
| 5966 |
ML 233 |
| Non-peptide apelin agonist |
| 4829 |
ML 239 |
| Breast cancer stem cell inhibitor |
| 5153 |
ML 240 |
| ATP-competitive inhibitor of p97 ATPase |
| 4777 |
ML 277 |
| Selective KV7.1 (KCNQ1) potassium channel activator; augments IKs current |
| 4880 |
ML 281 |
| STK33 inhibitor |
| 4976 |
ML 289 |
| Selective negative allosteric modulator of mGlu3 receptors |
| 5380 |
ML 297 |
| Selective Kir3.1/3.2 (GIRK1/2) channel activator |
| 4895 |
ML 298 hydrochloride |
| Selective PLD2 inhibitor |
| 5733 |
ML 311 |
| Inhibits Mcl-1-BIM interaction |
| 5700 |
ML 315 hydrochloride |
| Inhibitor of Clk and DYRK kinases |
| 6435 |
ML 323 |
| Potent and selective USP1-UAF1 allosteric inhibitor |
| 5625 |
ML 334 |
| Inhibitor of Keap1- Nrf2 interaction |
| 6887 |
ML 335 |
| Selective K2P2.1 (TREK-1) and K2P10.1 (TREK-2) activator |
| 4982 |
ML 337 |
| Selective negative allosteric modulator of mGlu3 receptors |
| 5943 |
ML 339 |
| Potent and selective hCXCR6 antagonist |
| 4586 |
ML 3403 |
| p38 inhibitor |
| 4945 |
ML 347 |
| Potent and selective ALK1 and ALK2 inhibitor |
| 5345 |
ML 348 |
| Selective and reversible lysophospholipase 1 (LYPLA1) inhibitor |
| 5344 |
ML 349 |
| Selective and reversible lysophospholipase 2 (LYPLA2) inhibitor |
| 6448 |
ML 351 |
| Selective 12/15 LOX inhibitor; active in vivo |
| 5387 |
ML 354 |
| Selective PAR4 antagonist |
| 5337 |
ML 365 |
| Potent and selective K2P3.1 (TASK-1) channel blocker |
| 5738 |
ML 382 |
| MRGPRX1 positive allosteric modulator |
| 6243 |
ML 385 |
| Nrf2 inhibitor; phenotypically lethal |
| 6888 |
ML 402 |
| Selective TREK channel activator |
| 6889 |
ML 418 |
| Kir 7.1 inhibitor; also inhibits Kir 6.2 |
| 6886 |
ML 67-33 |
| K2P2.1 (TREK-1), K2P10.1 (TREK-2) and K2P4.1 (TRAAK) channel activator |
| 4310 |
ML 7 hydrochloride |
| Selective inhibitor of myosin light chain kinase |
| 0431 |
ML 9 hydrochloride |
| Myosin light chain kinase inhibitor |
| 4746 |
ML SA1 |
| Activator of TRPML channels |
| 1885 |
MLCK inhibitor peptide 18 |
| Selective inhibitor of myosin light chain kinase |
| 4582 |
MLR 1023 |
| Selective allosteric activator of Lyn kinase |
| 6171 |
MLS 1547 |
| G protein-biased D2 partial agonist |
| 5756 |
MLi-2 |
| Potent and selective LRRK2 inhibitor |
| 7053 |
MM 07 |
| Apelin receptor biased agonist; exhibits bias for the G protein pathway |
| 5307 |
MM 102 |
| Potent WDR5/MLL interaction inhibitor |
| 3822 |
MM 11253 |
| RARγ-selective antagonist |
| 5992 |
MM 54 |
| Potent apelin antagonist |
| 0933 |
MM 77 dihydrochloride |
| 5-HT1A (postsynaptic) antagonist |
| 5683 |
MMAE |
| Potent dolastatin 10 analog; antitumor |
| 4511 |
MMF |
| Activator of Nrf2 pathway; primary metabolite of DMF (Cat. No. 4512) |
| 6858 |
MMG 11 |
| TLR2 antagonist |
| 3537 |
MMK 1 |
| Potent and selective FPR2 agonist |
| 2963 |
MMPIP hydrochloride |
| Potent and selective negative allosteric modulator of mGlu7 receptors |
| 0552 |
MMPX |
| PDE1 inhibitor |
| 5084 |
MN 64 |
| Potent and selective tankyrase inhibitor |
| 4388 |
MNI 137 |
| Selective negative allosteric modulator of group II mGlu receptors |
| 2224 |
MNI-caged-NMDA |
| Caged NMDA |
| 2225 |
MNI caged kainic acid |
| Caged kainic acid |
| 1490 |
MNI-caged-L-glutamate |
| Stable photoreleaser of L-glutamate |
| 2277 |
MNI-caged-D-aspartate |
| Caged D-aspartate; NMDA agonist |
| 2492 |
MNITMT |
| Novel, non-toxic immunosuppressive agent |
| 2877 |
MNS |
| Selective inhibitor of Src and Syk |
| 2568 |
MOG (35-55) |
| Encephalitogenic myelin oligodendrocyte glycoprotein fragment |
| 5770 |
MONNA |
| Potent TMEM16A (Anoctamin-1) blocker |
| 5508 |
MOPS |
| Widely used buffering agent |
| 5877 |
MOPS, sodium salt |
| Used as a buffering agent |
| 5888 |
MOPSO, free acid |
| Buffer; working pH range in aqueous solution: 6.2-7.6 |
| 5803 |
MP A08 |
| Selective ATP competitive SphK1 and 2 inhibitor; cell permeable |
| 5231 |
MPC 6827 hydrochloride |
| Inhibitor of microtubule polymerization; antimitotic and antitumor |
| 0973 |
MPDC |
| Potent inhibitor of L-glutamate uptake. Less activity as a substrate compared to its parent compound, L-trans-2,4-PDC (Cat. No. 0298) |
| 1035 |
8-M-PDOT |
| Melatonin agonist |
| 1212 |
MPEP hydrochloride |
| Potent mGlu5 antagonist; also positive allosteric modulator of mGlu4 receptors |
| 0661 |
2-MPMDQ |
| Potent, selective α1 antagonist. Also σ2 ligand |
| 1991 |
MPP dihydrochloride |
| Highly selective ERα antagonist |
| 5033 |
2-MPPA |
| Selective glutamate carboxypeptidase II (GCP II) inhibitor; orally bioavailable |
| 0853 |
MPPG |
| Group III and group II mGlu antagonist; more selective for group III than group II |
| 0783 |
N-MPPP Hydrochloride |
| Selective κ agonist |
| 7230 |
MPro N3 New |
| Coronavirus Mpro inhibitor |
| 0537 |
MR 16728 hydrochloride |
| Stimulates ACh release |
| 4041 |
MRE 3008F20 |
| Highly potent and selective adenosine A3 receptor antagonist |
| 3817 |
MRK 016 |
| α5-selective GABAA inverse agonist |
| 4000 |
MRK 560 |
| γ-secretase inhibitor; attenuates amyloid plaque deposition |
| 6803 |
MRK 740 |
| Potent PRDM9 inhibitor |
| 1217 |
MRS 1220 |
| Highly potent and selective hA3 antagonist |
| 1385 |
MRS 1334 |
| Potent, highly selective hA3 antagonist |
| 1584 |
MRS 1706 |
| Potent and selective A2B inverse agonist |
| 2752 |
MRS 1754 |
| Selective A2B antagonist |
| 0900 |
MRS 2179 tetrasodium salt |
| Selective P2Y1 antagonist |
| 2402 |
MRS 2211 |
| Competitive P2Y13 antagonist |
| 1203 |
MRS 2219 |
| Potentiates P2X1-mediated responses |
| 2158 |
MRS 2279 |
| Selective, high affinity P2Y1 antagonist |
| 2157 |
MRS 2365 |
| Highly potent and selective P2Y1 agonist |
| 2159 |
MRS 2500 tetraammonium salt |
| Highly potent and selective P2Y1 antagonist |
| 2146 |
MRS 2578 |
| Selective P2Y6 antagonist |
| 2915 |
MRS 2690 |
| Potent P2Y14 agonist |
| 2502 |
MRS 2693 trisodium salt |
| Selective P2Y6 agonist |
| 3884 |
MRS 2768 tetrasodium salt |
| Selective P2Y2 agonist |
| 5633 |
MRS 2905 |
| Potent and selective P2Y14 receptor agonist |
| 4260 |
MRS 2957 triethylammonium salt |
| Potent and selective P2Y6 agonist |
| 4261 |
MRS 4062 triethylammonium salt |
| Selective P2Y4 receptor agonist |
| 5428 |
MRS 5698 |
| High affinity and selective A3 agonist |
| 4585 |
MRT 10 |
| Smoothened (Smo) antagonist |
| 5134 |
MRT 67307 dihydrochloride |
| Salt inducible kinase (SIK) inhibitor |
| 5067 |
MRT 68601 hydrochloride |
| Potent TBK inhibitor |
| 5780 |
MRT 68921 dihydrochloride |
| Potent ULK inhibitor; inhibits autophagy |
| 5713 |
MS 023 dihydrochloride |
| Potent and selective type I PRMT inhibitor |
| 6299 |
MS 15203 |
| Potent and selective GPR171 partial agonist |
| 6298 |
MS 21570 |
| GPR171 antagonist |
| 4208 |
MS 245 oxalate |
| High affinity 5-HT6 antagonist |
| 6208 |
MS 275 |
| HDAC (Class I) inhibitor |
| 5173 |
MS 436 |
| Potent and selective BRD4(1) inhibitor |
| 5685 |
MS049 oxalate salt |
| Potent and selective PRMT4 and PRMT6 inhibitor |
| 5641 |
MSC 2032964A |
| Potent and selective ASK1 inhibitor; orally bioavailable |
| 5954 |
MSG 606 |
| Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist |
| 3424 |
γ1-MSH |
| Selective MC3 receptor agonist |
| 4272 |
[D-Trp8]-γ-MSH |
| Selective MC3 receptor agonist |
| 3013 |
[Nle4,D-Phe7]-α-MSH |
| Melanocortin receptor agonist |
| 2584 |
α-MSH |
| Endogenous melanocortin receptor agonist |
| 0803 |
MSOP |
| Specific group III mGlu antagonist |
| 0854 |
MSPG |
| Group III and group II mGlu antagonist |
| 2921 |
MTEP hydrochloride |
| Potent and selective mGlu5 antagonist |
| 0855 |
MTPG |
| Group II/group III mGlu antagonist; more selective for group II than group III |
| 5224 |
MTT |
| Reagent used in the measurement of cell proliferation |
| 0432 |
MY-5445 |
| PDE5 inhibitor |
| 6154 |
MZ 1 |
| (+)-JQ1 based PROTAC that selectively degrades BRD4 in cells |
| 3061 |
Macbecin I |
| Hsp90 inhibitor |
| 0479 |
Malonoben |
| Oxidative phosphorylation uncoupler |
| 5938 |
Mambalgin 1 |
| Selective ASIC1a inhibitor; analgesic |
| 6856 |
α-Mangostin |
| Inhibits proliferation and induces apoptosis selectively in pancreatic CSCs and cancer cell lines |
| 0935 |
Maprotiline hydrochloride |
| Noradrenalin re-uptake inhibitor |
| 3756 |
Maraviroc |
| Selective CCR5 antagonist |
| 3563 |
Margatoxin |
| Potent KV1.3 channel blocker |
| 2631 |
Marimastat |
| Broad spectrum MMP inhibitor |
| 1192 |
Mastoparan |
| Activates Gi and Go |
| 4949 |
MaxiPost |
| Potassium channel modulator; exerts subtype-specific effects |
| 2148 |
(±)-McN 5652 |
| Potent, orally active 5-HT uptake inhibitor; also inhibits noradrenalin and dopamine uptake in vitro |
| 1384 |
McN-A 343 |
| Selective M1 muscarinic agonist |
| 3982 |
Mdivi 1 |
| Selective dynamin inhibitor; attenuates mitochondrial division and apoptosis |
| 3873 |
MeBIO |
| Inactive analog of BIO (Cat. No. 3194) |
| 2281 |
2'-MeCCPA |
| Very selective and potent A1 receptor agonist |
| 2843 |
Mecamylamine hydrochloride |
| Non-competitive nAChR antagonist |
| 4245 |
Meclizine dihydrochloride |
| Human pregnane X receptor agonist; H1 antagonist |
| 5160 |
Medetomidine hydrochloride |
| Potent and highly selective α2 agonist |
| 6819 |
Mefloquine hydrochloride |
| Cx36 and Cx50 gap channel blocker; also antimalarial and antischistosomal |
| 6285 |
Megestrol Acetate |
| Synthetic progesterone analog |
| 1929 |
Melanocyte-stimulating hormone release inhibiting factor |
| Inhibitor of α-MSH release; inhibits opioid effects in vivo |
| 2566 |
Melanotan II |
| High affinity melanocortin receptor agonist |
| 3550 |
Melatonin |
| Endogenous hormone; agonist at MT1 and MT2 |
| 1193 |
Melittin |
| Inhibits Gs and stimulates Gi activity |
| 2495 |
Melperone hydrochloride |
| 5-HT2A antagonist; also D2 antagonist; neuroleptic |
| 4619 |
Melphalan |
| DNA alkylating agent; cytotoxic and antineoplastic |
| 0773 |
Memantine hydrochloride |
| NMDA antagonist; acts at ion channel site |
| 3276 |
Mephenytoin |
| CYP2C19 substrate. Anticonvulsant |
| 3636 |
Meptazinol hydrochloride |
| μ1 partial agonist |
| 0660 |
Mepyramine maleate |
| Selective H1 inverse agonist |
| 4103 |
6-Mercaptopurine |
| Purine analog; inhibits DNA and RNA synthesis |
| 3053 |
Mesopram |
| Orally active PDE4 inhibitor |
| 1644 |
Mesulergine hydrochloride |
| 5-HT2A and 5-HT2C antagonist; also D2-like partial agonist |
| 1443 |
Metastin (human) |
| Potent, endogenous ligand for kisspeptin receptor |
| 0590 |
Metergoline |
| 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7 |
| 2864 |
Metformin hydrochloride |
| Activator of LKB1/AMPK; antidiabetic agent |
| 1230 |
Methotrexate |
| Cytotoxic agent |
| 4920 |
Methoxy-X04 |
| Fluorescent amyloid β detector; brain penetrant |
| 1807 |
2-Methoxyestradiol |
| Apoptotic and antiangiogenic agent |
| 4814 |
Methoxyresorufin |
| Fluorometric CYP450 substrate |
| 0577 |
Methyl 2,5-dihydroxycinnamate |
| EGFR-kinase inhibitor |
| 0386 |
3-Methyl-GABA |
| Activator of GABA amino-transferase |
| 3513 |
N2-Methyl-L-arginine |
| Lysosomal system c L-arginine uptake inhibitor |
| 5698 |
1-Methyl-D-tryptophan |
| Indoleamine 2,3-dioxygenase (IDO) inhibitor |
| 3977 |
3-Methyladenine |
| Class III PI 3-kinase inhibitor; also inhibits autophagy |
| 0584 |
L-(-)-α-Methyldopa |
| Aromatic L-amino acid decarboxylase inhibitor |
| 3213 |
Methylene Blue |
| Biological stain |
| 3209 |
α,β-Methyleneadenosine 5'-triphosphate trisodium salt |
| Non-selective P2 agonist |
| 0549 |
Methylergometrine maleate |
| Active metabolite of methysergide (Cat. No. 1064) |
| 0588 |
5-Methylfurmethiodide |
| Potent muscarinic agonist |
| 0811 |
(±)-threo-3-Methylglutamic acid |
| EAAT2 and EAAT4 blocker |
| 0569 |
(R)-(-)-α-Methylhistamine dihydrobromide |
| Potent, standard H3 agonist |
| 0572 |
(S)-(+)-α-Methylhistamine dihydrobromide |
| H3 agonist, less active enantiomer |
| 2342 |
4-Methylhistamine dihydrochloride |
| Selective, high affinity H4 agonist |
| 0573 |
Nα-Methylhistamine dihydrochloride |
| Non-selective H3 agonist |
| 0558 |
2-Methyl-5-hydroxytryptamine hydrochloride |
| 5-HT3 agonist/potent 5-HT6 ligand |
| 0557 |
α-Methyl-5-hydroxytryptamine maleate |
| 5-HT2B agonist |
| 0776 |
(S)-Methylisothiourea sulfate |
| Highly selective iNOS inhibitor |
| 1042 |
N-Methyllidocaine iodide |
| Enhances biosynthesis of phosphatidylinositol |
| 1029 |
Methyllycaconitine citrate |
| Selective α7 neuronal nAChR antagonist |
| 4979 |
Methylmalonate |
| Succinate dehydrogenase inhibitor |
| 6109 |
Methylnaltrexone bromide |
| μ antagonist; peripherally restricted |
| 1812 |
Threo-methylphenidate hydrochloride |
| Inhibitor of dopamine and noradrenalin transporters. Psychomotor stimulant |
| 4819 |
Methylprednisolone |
| Glucocorticoid receptor agonist |
| 3017 |
1-Methylpsilocin |
| Potent and selective 5-HT2C agonist |
| 0566 |
N-Methylquipazine dimaleate |
| 5-HT3 agonist |
| 1624 |
2-Methylthioadenosine diphosphate trisodium salt |
| Potent agonist at P2Y1, P2Y12 and P2Y13 |
| 1062 |
2-Methylthioadenosine triphosphate tetrasodium salt |
| Non-selective P2 agonist |
| 1064 |
Methysergide maleate |
| 5-HT1/5-HT2 antagonist |
| 3256 |
Metoprolol tartrate |
| Selective β1 antagonist |
| 3292 |
Metyrapone |
| 11-β hydroxylase inhibitor |
| 1526 |
Mevastatin |
| HMG-CoA reductase inhibitor |
| 2596 |
Mexiletine hydrochloride |
| Na+ channel blocker; antiarrhythmic agent |
| 0997 |
Mianserin hydrochloride |
| 5-HT2 antagonist. Has moderate affinity for 5-HT6 |
| 2198 |
Mibefradil dihydrochloride |
| CaV3.x blocker |
| 3016 |
Miconazole nitrate |
| Azole antifungal agent |
| 2832 |
Midazolam hydrochloride |
| Benzodiazepine agonist |
| 1479 |
Mifepristone |
| Progesterone and glucocorticoid receptor antagonist |
| 4985 |
Miglitol |
| α-glucosidase inhibitor |
| 3117 |
Miglustat hydrochloride |
| α-glucosidase I and II inhibitor. Also inhibits ceramide-specific glycosyltransferases |
| 2604 |
Milameline hydrochloride |
| Muscarinic receptor agonist |
| 3286 |
Milnacipran hydrochloride |
| 5-HT and NA reuptake inhibitor (SNRI) |
| 1504 |
Milrinone |
| PDE3 inhibitor |
| 3268 |
Minocycline hydrochloride |
| Antibiotic. Displays neuroprotective effects |
| 0583 |
Minoxidil |
| Kir6 channel (KATP) opener |
| 7070 |
Mirabegron |
| Potent and selective β3 agonist |
| 3190 |
Mirin |
| MRN-ATM pathway inhibitor |
| 2018 |
Mirtazapine |
| Potent 5-HT2 antagonist; also 5-HT3, H1 and α2 antagonist; antidepressant |
| 2297 |
Misoprostol |
| Cytoprotective PGE1 analog |
| 4224 |
MitMAB |
| Dynamin inhibitor |
| 1489 |
Mithramycin A |
| Inhibitor of DNA and RNA polymerase |
| 6444 |
MitoMark Green I |
| Green fluorescent mitochondrial stain; cell permeable |
| 6445 |
MitoMark Red I |
| Red fluorescent mitochondrial stain; cell permeable |
| 4428 |
MitoPY1 |
| Fluorescent mitochondrial hydrogen peroxide indicator |
| 6898 |
Mitochondrial fusion promoter M1 |
| Mitochondrial fusion promoter |
| 5799 |
Mitoglitazone |
| Insulin sensitizer; exhibits low binding affinity at PPARγ |
| 3258 |
Mitomycin C |
| DNA cross-linking antitumor agent |
| 4250 |
Mitoxantrone dihydrochloride |
| Topoisomerase II inhibitor; immunosuppressive and antineoplastic agent |
| 1875 |
Mixed Adrenergic Tocriset™ |
| Selection of 5 mixed adrenoceptor ligands (Cat. Nos. 0888, 0425, 1747, 0623 and 0952) |
| 1825 |
Mixed NMDA Receptor Tocriset™ |
| Selection of 5 mixed NMDA receptor ligands (Cat. Nos. 0114, 0312, 0106, 0924 and 1241) |
| 1829 |
Mixed mGlu Receptor Tocriset™ |
| Selection of 5 mixed mGlu receptor ligands (Cat. Nos. 0805, 0975, 0103, 0337 and 1209) |
| 4395 |
Moclobemide |
| Reversible MAO-A inhibitor |
| 1811 |
Modafinil |
| Psychostimulant |
| 6131 |
(R)-Modafinil |
| Dopamine uptake inhibitor |
| 4115 |
Mometasone furoate |
| Synthetic corticosteroid; anti-inflammatory agent |
| 1305 |
Monastrol |
| Selective inhibitor of mitotic kinesin Eg5 |
| 5223 |
Monensin sodium salt |
| Sodium ionophore; antibacterial agent |
| 5904 |
Montelukast sodium |
| CysLT1 and GPR17 antagonist |
| 5158 |
Morphine hydrochloride |
| Narcotic opioid analgesic |
| 2844 |
Mosapride citrate |
| 5-HT4 agonist and 5-HT3 antagonist |
| 2264 |
Motilin (human, porcine) |
| Endogenous peptide regulator of gastrointestinal motility |
| 2282 |
Moxonidine hydrochloride |
| I1 receptor and α2-adrenoceptor agonist (I1 > α2) |
| 5562 |
Mps BAY 2a |
| Potent and selective Mps1 kinase inhibitor |
| 5142 |
Mps1-IN-1 dihydrochloride |
| Selective Mps1 kinase inhibitor |
| 6366 |
Muramyl Dipeptide |
| Activates NOD2 receptors |
| 3816 |
Muristerone A |
| Stimulates Bcl-XL mRNA transcription; antiapoptotic |
| 3074 |
(+)-Muscarine iodide |
| Muscarinic receptor agonist |
| 0289 |
Muscimol |
| Potent GABAA agonist; also GABAA-ρ partial agonist |
| 4102 |
Mycophenolate mofetil |
| Inosine monophosphate dehydrogenase (IMPDH) inhibitor |
| 1505 |
Mycophenolic acid |
| Inosine monophosphatase dehydrogenase (IMPDH) inhibitor |
| 3399 |
Myelin Basic Protein (87-99) |
| Major antigenic component implicated in the pathophysiology of multiple sclerosis |
| 6189 |
Myricetin |
| Irreversible TrxR inhibitor |
| 0567 |
(±)-Myristoylcarnitine chloride |
| Intermediate in lipid metabolism |